Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 6:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 813 matching trials from the live ClinicalTrials.gov search.
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Dexmethylphenidate, Mixed Amphetamine Salts, ER, placebo
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
9 Years to 17 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Chicago, Illinois • Northbrook, Illinois
Conditions
Attention Deficit Disorder
Interventions
Extended-release bupropion hydrochloride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
21
States / cities
Phoenix, Arizona • Chula Vista, California • Lafayette, California + 18 more
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Short Acting Methylphenidate, Long Acting Methylphenidate
Drug
Lead sponsor
BRC Operations Pty. Ltd.
Industry
Eligibility
6 Years to 17 Years
Enrollment
1,344 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2019
U.S. locations
5
States / cities
Colton, California • Tarzana, California • Englewood Cliffs, New Jersey + 2 more
Conditions
ADHD
Interventions
Not listed
Lead sponsor
Rhode Island Hospital
Other
Eligibility
10 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
East Providence, Rhode Island
Conditions
ADHD
Interventions
Digital Health Intervention Group
Behavioral
Lead sponsor
University of California, Riverside
Other
Eligibility
8 Years to 12 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Irvine, California • Riverside, California
Conditions
Disruptive Behavior Disorders, Conduct Disorder, Oppositional Defiant Disorder, Attention-deficit/Hyperactivity Disorder
Interventions
Psychotherapy
Behavioral
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
8 Years to 13 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2037
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
ADHD
Interventions
Calcitriol, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
New Haven, Connecticut
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Methylphenidate Treatment of Attention Deficits in Epilepsy

NCT02178995
Conditions
Epilepsy, Cognitive Deficits, Attention Deficits
Interventions
Methylphenidate
Drug
Lead sponsor
Kimford Jay Meador
Other
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Palo Alto, California
Active, not recruiting Not applicable Interventional

tRNS Treatment for ADHD Symptoms

NCT06189703
Conditions
ADHD
Interventions
tRNS
Device
Lead sponsor
Innosphere
Industry
Eligibility
7 Years to 12 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
Boston, Massachusetts • Rochester, Minnesota • Houston, Texas
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Quillivant Oral Suspension XR, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 12 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Irvine, California • Las Vegas, Nevada
Completed Not applicable Interventional Results available

Training Attentional Awareness and Control in ADHD

NCT02489279
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Sustained Attention Control (SAC) Method, Scrabble
Behavioral
Lead sponsor
Think Now Incorporated
Industry
Eligibility
18 Years to 40 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Healthy Adult Participants
Interventions
Centanafadine
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Lenexa, Kansas
Conditions
ADHD Specifically With Executive Function Impairment
Interventions
SPD489, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
39
States / cities
Little Rock, Arkansas • Rolling Hills Estates, California • San Diego, California + 34 more
Conditions
ADHD
Interventions
galantamine HBr
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 58 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Cambridge, Massachusetts
Conditions
Disruptive Mood Dysregulation Disorder, Attention Deficit Hyperactivity Disorder, Normal Physiology
Interventions
Affective Posner fMRI frustration induction task
Behavioral
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
8 Years to 17 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Placebo, OROS-methylphenidate
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Years to 12 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Sleep Intervention, Melatonin
Behavioral · Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 12 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Control of Cognition (Naltrexone, Methylphenidate, and ADHD Study (NMAS))

NCT01993108
Conditions
Healthy, Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate, Naltrexone, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 35 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Attention-deficit Hyperactivity Disorder (ADHD)
Interventions
NFC-1
Drug
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
12 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
SPN-810, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
38
States / cities
Culver City, California • Orange, California • Colorado Springs, Colorado + 33 more
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
SHP465, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years to 17 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
36
States / cities
Dothan, Alabama • Orange, California • San Diego, California + 31 more
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Atomoxetine, Sugar Pill
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
7 Years to 12 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Cincinnati, Ohio
Completed No phase listed Observational Accepts healthy volunteers

Sleep Dysfunction and Neurocognitive Outcomes in Adolescent ADHD

NCT02897362
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
13 Years to 17 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Motivated Behavior in Adults With and Without ADHD

NCT02630017
Conditions
ADHD
Interventions
ADHD methylphenidate first, placebo second, ADHD placebo first, methylphenidate second, Non-ADHD methylphenidate first, placebo second, Non-ADHD placebo first, methylphenidate second
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 45 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Little Rock, Arkansas • Durham, North Carolina